• Logistic complications create high demand for the expertise of comparator suppliers • Reference batches can be sourced from...

• Phase II signals encouraging for positive Phase III translation • Capsaicin as stratification tool shows promise for responder...

• Remsima use may be forced ahead of Remicade, but not Humira or Enbrel • Celltrion needs to emphasize Remsima clinical...

• Enrollment criteria expanded mid-trial to reflect shifting treatment landscape • Inhibiting MEK elicits enthusiasm for NRAS...

Over the last decade or so, I have observed a tempering of what was once a large and growing interest in stem cell therapies by patients,...

• Superiority to standard therapy bodes well for approvals • Regulators may require dropout explanation • Good potential for first...

• Historical responses meaningful, but approvability based on transfusion changes unclear • Gene expression based screening could...

• Marginal OS benefit found in Asian patients in previous trial lends optimism • Vaccine combination with PD1/PDL-1 checkpoint...

• Valuations unreliable given large timeframe to market • Likely EU/US pricing pressures to impact revenue forecasting • Combined...

"Targets T790M mutation to overcome EGFR inhibitor resistance Could be effective in the first-line setting as well Selectivity...